GENENTA SCIENCE SPA - ADR (GNTA) Stock Overview
USA - NASDAQ:GNTA - US36870W1009 - ADR
GNTA Key Statistics, Chart & Performance
The current stock price of GNTA is 3.01 USD. In the past month the price decreased by -7.82%. In the past year, price decreased by -44.77%.
GNTA Latest News, Press Relases and Analysis
GNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.26 | 397.72B | ||
| AMGN | AMGEN INC | 13.38 | 157.08B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 89.25 | 50.61B | ||
| INSM | INSMED INC | N/A | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.58B | ||
| NTRA | NATERA INC | N/A | 26.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.24 | 21.68B |
Related stock screener links
About GNTA
Company Profile
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Company Info
GENENTA SCIENCE SPA - ADR
Via Olgettina 58
Milan MILANO IT
Employees: 13
GENENTA SCIENCE SPA - ADR / GNTA FAQ
Can you describe the business of GENENTA SCIENCE SPA - ADR?
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
What is the stock price of GENENTA SCIENCE SPA - ADR today?
The current stock price of GNTA is 3.01 USD. The price increased by 25.42% in the last trading session.
What is the dividend status of GENENTA SCIENCE SPA - ADR?
GNTA does not pay a dividend.
How is the ChartMill rating for GENENTA SCIENCE SPA - ADR?
GNTA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for GNTA stock?
GENENTA SCIENCE SPA - ADR (GNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.57).
Would investing in GENENTA SCIENCE SPA - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNTA.
GNTA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GNTA. When comparing the yearly performance of all stocks, GNTA is a bad performer in the overall market: 93.54% of all stocks are doing better.
GNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GNTA. GNTA has a great financial health rating, but its profitability evaluates not so good.
GNTA Financial Highlights
Over the last trailing twelve months GNTA reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 23.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.12% | ||
| ROE | -71.32% | ||
| Debt/Equity | 0 |
GNTA Forecast & Estimates
8 analysts have analysed GNTA and the average price target is 21.42 USD. This implies a price increase of 611.63% is expected in the next year compared to the current price of 3.01.